Drug intelligence / Profile preview

technetium tc99m mertiatide

Development stage
Approved
Lead developer
Mallinckrodt
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Technetium tc99m mertiatide is a radiopharmaceutical agent used in nuclear medicine primarily for dynamic renal imaging. After intravenous injection, it rapidly binds to plasma proteins and is excreted mainly via **active tubular secretion** with some contribution from glomerular filtration. The radiolabeled compound emits gamma rays detectable by gamma cameras, allowing assessment of renal perfusion, function, drainage, and detection of congenital or acquired kidney abnormalities, obstruction, or calculi in adults and children. The agent is widely used to indirectly evaluate effective renal plasma flow, particularly in patients with possible renovascular hypertension, chronic kidney disease, and post-renal transplantation surveillance.

Brand names
Technescan Mag3
Other names
technetium (99mTc) mertiatidetc-99m mertiatidetc99m mertiatidetc 99m mertiatidetechnetium-99m mertiatidetechnetium99m mertiatidetechnetium 99m mertiatide
02

Targets

ABCC4 (Multidrug resistance-associated protein 4)OAT1 (Organic anion transporter 1)SLC22A8 (Organic anion transporter 3)ABCC2 (ATP-binding cassette sub-family C member 2)

Beyond the preview

Go deeper on technetium tc99m mertiatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on technetium tc99m mertiatide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call